
Synaffix Announces Expansion of ADC Collaboration with MacroGenics
Synaffix announces the expansion of their collaboration with biopharmaceutical company MacroGenics, Inc., to a value of up to $2.2B plus up to high single-digit royalties. Under this new expanded deal, MacroGenics, Inc. will pursue up to seven of the ADC programs, helping to further contribute towards the transformation of cancer treatment.